Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Atsushi Shinagawa"'
Autor:
Shinichi Ogawa, Tatsuhiro Sakamoto, Ryota Matsuoka, Kantaro Ishitsuka, Yasuko Ogino, Ayano Sootome, Kenichi Makishima, Chikashi Yoshida, Yufu Ito, Seiichi Shimizu, Takuya Suyama, Atsushi Shinagawa, Takayoshi Ito, Naoshi Obara, Manabu Kusakabe, Mamiko Sakata‐Yanagimoto, Yasushi Miyazaki, Yasuhito Nannya, Shigeru Chiba
Publikováno v:
Cancer Reports, Vol 7, Iss 1, Pp n/a-n/a (2024)
Abstract Background Hypomethylating agents, including azacytidine (AZA), are standard therapeutics for patients with high‐risk myelodysplastic syndromes (MDS), a group of myeloid neoplasms. However, treatment schedules are not unified in real‐wor
Externí odkaz:
https://doaj.org/article/f09fa49297404012bf6c2f22d92a991c
Autor:
Yuji Okamoto, Mitsuhito Hirano, Kai Morino, Masashi K. Kajita, Shinji Nakaoka, Mayuko Tsuda, Kei-ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Hisashi Wakita, Kaichi Nishiwaki, Arinobu Tojo, Kazuyuki Aihara
Publikováno v:
npj Systems Biology and Applications, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR-ABL1 tyrosine kinase. Although ABL1-specific tyrosine kinase inhibitors (TKIs) including nilotinib have dramatically improved the prognosis of patients with CM
Externí odkaz:
https://doaj.org/article/58f4e055c3eb45ed81510406b1170155
Autor:
Kaichi Nishiwaki, Kei‐ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Arinobu Tojo, Hisashi Wakita
Publikováno v:
Cancer Medicine, Vol 9, Iss 11, Pp 3742-3751 (2020)
Abstract For patients who have chronic myeloid leukemia (CML), one of the primary treatment options is administration of nilotinib 300 mg twice daily (BID). In previous studies which compared outcomes associated with nilotinib or imatinib treatment,
Externí odkaz:
https://doaj.org/article/d6cec3dbf9054fe0b643aba4e9c79cd9
Autor:
Hidekazu Nishikii, Naoki Kurita, Atsushi Shinagawa, Tatsuhiro Sakamoto, Manabu Kusakabe, Yasuhisa Yokoyama, Takayasu Kato, Mamiko Sakata-Yanagimoto, Naoshi Obara, Yuichi Hasegawa, Naoya Nakamura, Shigeru Chiba
Publikováno v:
Case Reports in Hematology, Vol 2019 (2019)
A 38-year-old woman with aggressive clinical course of chronic lymphocytic leukemia (CLL) was treated with 8 courses of R-CHOP. Clinical remission was achieved, while B-cell clonality remained. Allogeneic hematopoietic stem cell transplantation was p
Externí odkaz:
https://doaj.org/article/bef8eb0569c7426d9c6f139d583a4b7c
Autor:
Masato Mitsuhashi, Katsuya Endo, Kazuhiko Obara, Hiroshi Izutsu, Taishi Ishida, Norio Chikatsu, Atsushi Shinagawa
Publikováno v:
Clinical Medicine Insights: Blood Disorders, Vol 1 (2008)
Apoptosis was induced in heparinized human whole blood by 3 different ways (radiation, bleomycin, or etoposide), and various mRNA were quantified using the method we reported (Clin. Chem. 2006; 52:634-642). We found that cyclin-dependent kinase inhib
Externí odkaz:
https://doaj.org/article/75e15c9a426643eab322e26ed61fadcd
Purpose Vincristine (VCR) often induces peripheral neuropathy (PN) as an adverse event. Currently, there is no consensus about prevention of vincristine-induced PN (VIPN). In this study, we aimed to investigate the efficacy of compression therapy usi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47e68d6e6d6922bad118490b6bc9c344
https://doi.org/10.21203/rs.3.rs-2811473/v1
https://doi.org/10.21203/rs.3.rs-2811473/v1
Autor:
Noboru Asada, Jun Ando, Satoru Takada, Chikashi Yoshida, Kensuke Usuki, Atsushi Shinagawa, Kenichi Ishizawa, Toshihiro Miyamoto, Hiroatsu Iida, Nobuaki Dobashi, Sumiko Okubo, Hideyuki Honda, Tomomi Soshin, Yasuko Nishimura, Atsuko Tsutsui, Harumi Mukai, Kazuhito Yamamoto
Publikováno v:
Japanese Journal of Clinical Oncology.
Background In a Phase 3 international clinical trial (VIALE-C), venetoclax plus low-dose cytarabine improved the response rate and overall survival versus placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia who we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::890094c59970f17ec0eba76a109652f7
https://doi.org/10.1093/jjco/hyad027
https://doi.org/10.1093/jjco/hyad027
Autor:
Shigeru Chiba, Koichi Ohshima, Seishi Ogawa, Shintaro Yanagimoto, Manabu Kusakabe, Naoshi Obara, Hidekazu Nishikii, Yuji Sato, Takuya Suyama, Atsushi Shinagawa, Shinichiro Sukegawa, Haruka Momose, Kantaro Ishitsuka, Yusuke Kiyoki, Olivier A. Bernard, Kota Fukumoto, Koichi Hashimoto, Yasuhito Nannya, Hiroaki Miyoshi, Sharna Tanzima Nuhat, Manabu Fujisawa, Mamiko Sakata-Yanagimoto, Tran B. Nguyen
Supplemental methods, results, figures, and tables.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c815463888ba17b5a827e7ef168711af
https://doi.org/10.1158/0008-5472.22424491
https://doi.org/10.1158/0008-5472.22424491
Autor:
Shigeru Chiba, Koichi Ohshima, Seishi Ogawa, Shintaro Yanagimoto, Manabu Kusakabe, Naoshi Obara, Hidekazu Nishikii, Yuji Sato, Takuya Suyama, Atsushi Shinagawa, Shinichiro Sukegawa, Haruka Momose, Kantaro Ishitsuka, Yusuke Kiyoki, Olivier A. Bernard, Kota Fukumoto, Koichi Hashimoto, Yasuhito Nannya, Hiroaki Miyoshi, Sharna Tanzima Nuhat, Manabu Fujisawa, Mamiko Sakata-Yanagimoto, Tran B. Nguyen
Recurrent hotspot (p.Gly17Val) mutations in RHOA encoding a small GTPase, together with loss-of-function mutations in TET2 encoding an epigenetic regulator, are genetic hallmarks of angioimmunoblastic T-cell lymphoma (AITL). Mice expressing the p.Gly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b657c26606172804a23dac008ee99a48
https://doi.org/10.1158/0008-5472.c.6511786.v1
https://doi.org/10.1158/0008-5472.c.6511786.v1
Autor:
Hagop M. Kantarjian, Catherine L. Miller, Jalaja Potluri, Brenda Chyla, Yinghui Duan, Monique Dail, Roberto M. Lemoli, Atsushi Shinagawa, B. Douglas Smith, David A. Rizzieri, Marina Konopleva, Walter Fiedler, Arnaud Pigneux, Martha L. Arellano, Courtney D. DiNardo, Daniel A. Pollyea
Purpose:To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with IDH1/2-mutant (mut) acute myeloid leukemia (AML).Patients and Methods:Data were pooled from patients enrolled in a phase III study (NCT02993523)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25065976dfc434e19afcc1a8433e5bbf
https://doi.org/10.1158/1078-0432.c.6532287.v1
https://doi.org/10.1158/1078-0432.c.6532287.v1